0000000000714101

AUTHOR

S. Purvina

showing 2 related works from this author

Homocysteine and MTHFR C677T polymorphism in children and adolescents with psychotic and mood disorders

2013

High level of homocysteine (Hcy) is risk factor of schizophrenia and mood disorders.The aim was to detect a serum level of Hcy, examine the associations between the level of Hcy, methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and clinical properties for patients with schizophrenia, mood disorders and in a control group.There were 88 patients with schizophrenia, 28 with affective disorders and 94 from the control group. The Hamilton Anxiety Scale (HAM-A) was performed to study anxiety, the Hamilton Depression Scale (HAM-D) to study depression and the Brief Psychiatric Rating Scale (BPRS) to study severity of schizophrenia. The level of Hcy was stated by isocratic high-pe…

Malemedicine.medical_specialtyAdolescentHomocysteinePolymerase Chain Reactionbehavioral disciplines and activitieschemistry.chemical_compoundmental disordersBrief Psychiatric Rating ScalemedicineHumansRisk factorChildPsychiatryHomocysteineMethylenetetrahydrofolate Reductase (NADPH2)DNA PrimersPolymorphism GeneticBase SequencebiologyMood DisordersCase-control studymedicine.diseaseVitamin B 12Psychiatry and Mental healthchemistryMood disordersSchizophreniaCase-Control StudiesMethylenetetrahydrofolate reductaseSchizophreniabiology.proteinAnxietyFemalemedicine.symptomPsychologyNordic Journal of Psychiatry
researchProduct

Trends in individual reimbursement of orphan drugs in Latvia in 2008–2011

2014

Orphan drugs (ODs) are medicinal products intended for diagnosis, prevention or treatment of life-threatening or very serious diseases affecting less than 5 in 10 000 people in the European Union (EU). These drugs are called “orphans” because the pharmaceutical industry has little interest, under normal market conditions, in developing and marketing products intended for only a small number of patients suffering from very rare conditions. Because of the small market, ODs are often very expensive. Whereas decisions surrounding orphan designation and marketing authorization of ODs are taken at the EU level, decisions governing pricing and reimbursement of ODs are a member state responsibility…

Actuarial sciencebusiness.industryDrug reimbursementMarketing authorizationlcsh:Social Scienceslcsh:HOrphan drugMember stateMedicinemedia_common.cataloged_instancePer patient per yearEuropean unionbusinessReimbursementPharmaceutical industrymedia_commonSHS Web of Conferences
researchProduct